SCHEMBL10219787

SCHEMBL10219787

CC(c1ccc(-c2ccccc2)nc1)n1cnc2ccccc21

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.68
MEN1 O00255 1/20 0.68
HPGD P15428 1/20 0.68
HSD17B10 Q99714 1/20 0.68
CYP11B1 P15538 9/20 0.56
CYP11B2 P19099 9/20 0.56
FFAR1 O14842 1/20 0.40
APAF1 O14727 1/20 0.38
MAPT P10636 1/20 0.38
PTK2B Q14289 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HTT P42858 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
AURKA O14965 1/20 0.37
AURKB Q96GD4 1/20 0.37
MET P08581 1/20 0.36
DHFR P00374 1/20 0.36
NR1I2 O75469 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15761425 0.84 CYP11B1 (0.60) KMT2AMEN1HPGDHSD17B10CYP11B1
SCHEMBL10219789 0.84 CYP11B1 (0.58) KMT2AMEN1HPGDHSD17B10CYP11B1
SCHEMBL10219772 0.82 CYP11B1 (0.55) KMT2AMEN1HPGDHSD17B10CYP11B1
SCHEMBL15540388 0.82 MEN1 (1.00) KMT2AMEN1HPGDHSD17B10CYP11B1
SCHEMBL15539513 0.82 MEN1 (1.00) KMT2AMEN1HPGDHSD17B10CYP11B1
SCHEMBL3304570 0.82 MEN1 (1.00) KMT2AMEN1HPGDHSD17B10CYP11B1
SCHEMBL10219778 0.77 CYP11B1 (0.70) CYP11B1CYP11B2FFAR1DHFR
Hydrochloric Acid SCHEMBL29006873 0.75 MEN1 (0.74) KMT2AMEN1HPGDHSD17B10APAF1
SCHEMBL1688799 0.73 CYP11B1 (0.56) CYP11B1CYP11B2FFAR1DHFR
SCHEMBL4233005 0.73 MEN1 (0.66) KMT2AMEN1HPGDHSD17B10CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9394290-B2 Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases UNIVERSITAET DES SAARLANDES CAMPUS SAARBRUECKEN (DE) 2016-07-19 US disclosed
US-9394290-B2 Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases UNIVERSITAET DES SAARLANDES CAMPUS SAARBRUECKEN (DE) 2016-07-19 US disclosed
US-20140155407-A1 SELECTIVE CYP11B1 INHIBITORS FOR THE TREATMENT OF CORTISOL DEPENDENT DISEASES UNIVERSITAET DES SAARLANDES (DE) 2014-06-05 US disclosed
US-20140155407-A1 SELECTIVE CYP11B1 INHIBITORS FOR THE TREATMENT OF CORTISOL DEPENDENT DISEASES UNIVERSITAET DES SAARLANDES (DE) 2014-06-05 US disclosed
WO-2012052540-A1 SELECTIVE CYP11B1 INHIBITORS FOR THE TREATMENT OF CORTISOL DEPENDENT DISEASES UNIVERSITAET DES SAARLANDES (DE) 2012-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140155407-A1 SELECTIVE CYP11B1 INHIBITORS FOR THE TREATMENT OF CORTISOL DEPENDENT DISEASES HSD11B1, CYP11B1, HSD11B2 KMT2A 2768/4885MEN1 397/4885HPGD 359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.